What is one disadvantage of alteplase compared to streptokinase?

The choice highlighting higher cost as a disadvantage of alteplase compared to streptokinase is accurate because alteplase is a recombinant tissue plasminogen activator (rtPA) that is typically more expensive due to its complex manufacturing process. In contrast, streptokinase is derived from bacterial sources and is generally less expensive, making it accessible for a wider range of patients and healthcare settings.

While efficacy can vary based on specific clinical scenarios and patient populations, alteplase is often preferred for its targeted mechanism and rapid action in certain types of thrombotic events, suggesting that its efficacy may not be a disadvantage in many cases. Additionally, both agents are utilized in different capacities depending on the clinical context, which addresses the notion of limited clinical use; alteplase has a broad spectrum of uses, particularly in acute management situations like ischemic stroke and myocardial infarction.

Lastly, while there are risks of bleeding associated with both alteplase and streptokinase, the risk dynamics can depend on many factors, including dosage and patient characteristics, rather than being a straightforward disadvantage of alteplase. Hence, highlighting the higher cost as the answer effectively captures a significant consideration when comparing these two thrombolytic agents.